Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
NCT03390738
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Sponsor withdrew funding for Nivolumab
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Nivolumab
Sponsor
The University of Hong Kong